Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its lead drug candidate Lucid-MS for multiple sclerosis while simultaneously generating revenue from its commercial product unbuzzd, according to Executive Co-Chairman and Co-Founder Anthony Durkacz in a recent BioMedWire Podcast. Durkacz outlined the company's strategy to address mobility damage caused by MS through Lucid-MS, which has shown promise in preclinical models by preventing and reversing myelin degradation. The company has filed an investigational new drug application for a Phase 2 clinical trial, which could mark the first administration of Lucid-MS to human MS patients.
Quantum BioPharma's dual approach includes both clinical-stage pharmaceutical development and commercial opportunities. The company's unbuzzd product, designed to accelerate alcohol metabolism, is already available on the market. Quantum BioPharma retains 19.84% ownership of Unbuzzd Wellness Inc. (UWI), the company that markets unbuzzd, and receives royalty payments of 7% of sales until $250 million is reached, after which the royalty drops to 3% in perpetuity. This commercial revenue stream supports the company's broader research and development efforts.
The company is focused on building a portfolio of innovative assets for neurodegenerative, metabolic, and alcohol-misuse conditions. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., Quantum BioPharma is developing Lucid-MS as a patented new chemical entity. The potential of Lucid-MS to address myelin degradation, a key mechanism in MS, represents a significant opportunity for patients with limited treatment options.
Durkacz emphasized the importance of the upcoming Phase 2 trial, which could provide critical data on the drug's efficacy and safety in humans. The company's strategy of combining clinical development with commercial products like unbuzzd aims to create a sustainable business model that funds long-term research. Investors can find the latest news and updates on QNTM at the company's newsroom at https://ibn.fm/QNTM.
For more details on Quantum BioPharma's pipeline and commercial strategy, the full podcast interview is available at https://ibn.fm/IWnPQ. The company's approach reflects a broader trend in biopharma where early-stage companies leverage commercial products to finance drug development, potentially reducing reliance on external funding and dilutive financing.
